Generic and biosimilar medicines are a proven solution to lowering drug costs, and the use of these medicines saved more than $313 billion in 2019 alone. At a time of high economic insecurity, access to more-affordable generic and biosimilars means patients are more likely to fill and use a generic drug prescription.
WASHINGTON, DC (January 21, 2020) — The Association for Accessible Medicines (AAM) strongly endorses the Biden administration’s executive orders to strengthen America’s response to the COVID pandemic. Generic medicines have been instrumental in treating COVID patients with severe conditions, serving as a bridge until the COVID vaccines are widely available. AAM’s members are ready to partner with the Biden administration to ensure reliable and predictable access to these vital therapies.
This article first appeared in Chain Drug Review on January 5, 2021 as Pharmacy Outlook: Dan Leonard.
Sandoz, the largest medicines provider in Europe and a major player globally, has a U.S. headquarters in Princeton, NJ. The Novartis division’s robust response to the COVID-19 pandemic has taken many forms:
Affordability. In early June, CEO Richard Saynor penned a LinkedIn post pledging:
Based in Toronto, Canada, Apotex also operates in the United States, Mexico and India. The company employs close to 8,000 people worldwide in manufacturing, R&D and commercial operations. Its Apobiologix division focuses on biosimilars development.
Here are some of Apotex’s most recent endeavors with the biggest impact:
WASHINGTON, DC (August 6, 2020) — Developers of generic and biosimilar medicines support diversification of the pharmaceutical supply chain and are working with policymakers to add to our significant manufacturing presence in the United States. The generic industry already makes tens of billions of doses of safe, effective and affordable medicines here in America each year and drafted recommendations to increase that production capacity – “A Blueprint for Enhancing the Security of the U.S.
The U.S. generics and biosimilars industry, makers of 90% of our nation's prescription medicines, has a plan to "#SecureOurMeds." We already produce billions of doses of medicine right here in America, and our plan ensures continued patient access through #COVID and beyond.
Find out more about our path forward: https://accessiblemeds.org/blueprint
Steve Giuli works at Apotex as Vice President, Government Affairs & Trade Relations. Steve is proud to be a part of the generic drug industry that saves and improves patients' lives. AAM is recognizing dedicated people like Steve and his peers across the generics and biosimilars industry who show up each day for U.S. patients.
AAM’s Blueprint for Enhancing the Security of the U.S. Pharmaceutical Supply Chain and documents like it provide lawmakers with the ingredients for achieving a legislative goal.
Last week the U.S. Department of Health and Human Services announced a grant worth up to $812 million for a public-private partnership to manufacture COVID-related medicines in the United States.